Highest-materiality recent filing
Mosaic ImmunoEngineering extends Oncotelic acquisition term sheet to June 30, 2025
Binding term sheet for acquisition of Oncotelic's necroptosis cancer therapies and AI tech extended to June 30, 2025.
Director Carlton Johnson resigns from Mosaic ImmunoEngineering board, effective July 23, 2024
Carlton Johnson notified the Board of his resignation effective immediately on July 23, 2024.
Mosaic ImmunoEngineering CFO Paul Lytle moves to part-time, pay cut to $1,600/month
CFO Paul Lytle reduced to part-time effective June 1, 2024, max 8 hours/month, monthly rate $1,600.
Mosaic ImmunoEngineering changes auditor; KMJ resigns, Rose Snyder & Jacobs appointed
KMJ Corbin & Company resigned on May 21, 2024, after its partners joined Crowe LLP.
Mosaic to acquire Oncotelic's clinical necroptosis cancer assets for up to $30M in stock
Binding term sheet signed April 26, 2024; acquisition includes VDA necroptosis therapies and AI platform.
Mosaic ImmunoEngineering announces passing of director Gloria Felcyn
Director Gloria Felcyn died on April 17, 2024.
CWRU terminates Mosaic's CPMV license for lead candidate MIE-101 over ~$407K unpaid IP fees
Effective March 22, 2024, CWRU terminated the exclusive worldwide license agreement due to financial default.
Mosaic ImmunoEngineering receives $300k for preferred shares; stock moving to OTC Pink
Redeemed remaining 910k Series A Preferred shares for $300k lump sum ($0.33/share), received June 22, 2023.
Nicole Steinmetz, Ph.D., resigned as director and acting CSO effective May 2, 2023.
Mosaic enters redemption agreement for $840K in Series A Preferred; initial $336K received
Holocom to redeem 2.1M Series A Preferred shares for $840K total; initial payment of $336K due July 11, 2022.
Licensed technology covers cowpea mosaic virus (CPMV)-based oncology treatments for human and companion animal cancers.
Mosaic ImmunoEngineering raises $342K via 8% convertible notes with board participation
Issued $342,632 principal of 8% convertible notes to 16 accredited investors; 5 board members invested $155,000 combined.
On July 23, 2024, Mr. Carlton Johnson notified the Board of Directors (the “Board”) of Mosaic ImmunoEngineering, Inc. (the “Company”) of his resignation from the Board effective immediately.
Mr. Paul Lytle, EVP, Chief Financial Officer of the Company, agreed to amend Mr. Lytle’s employment terms from full time status to part time status, not to exceed eight (8) hours per month effective June 1, 2024
Mosaic ImmunoEngineering, Inc. (the “Company”) is deeply saddened to announce that director Ms. Gloria Felcyn passed away on April 17, 2024.
On May 2, 2023, Nicole Steinmetz, Ph.D., advised the board of directors of Mosaic ImmunoEngineering, Inc. (the “Company”) of her intention to resign as a member of the board of directors and acting Chief Scientific Officer effective immediately.
Max materiality 0.85 · Median 0.55 · Most common event other_material